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  19 
Abstract 20 
Telaprevir, a protease inhibitor, was used alongside PEGylated interferon- and ribavirin to 21 
treat hepatitis C viral infections. The triple regimen proved successful; however, the 22 
appearance of severe skin reactions alongside competition from newer drugs restricted its use. 23 
Skin reactions presented with a delayed onset indicative of a T-cell mediated reaction. Thus, 24 
the aim of this study was to investigate whether telaprevir and/or its diastereomer, which is 25 
generated in humans, activates T-cells. Telaprevir in its S-configured therapeutic form and the 26 
R-diastereomer were cultured directly with PBMC from healthy donors prior to the generation 27 
of T-cell clones by serial dilution. Drug-specific CD4+ and CD8+ T-cell clones responsive to 28 
telaprevir and the R-diastereomer were generated and characterised in terms of phenotype and 29 
function. The clones proliferated in a dose-dependent manner and secreted IFN-γ, IL-13, and 30 
granzyme B in response to culture with telaprevir and the diastereomer at the same 31 
concentrations. In contrast, the telaprevir M11 metabolite did not stimulate T-cells. The CD8+ 32 
T-cell response was MHC I-restricted and dependent on the presence of soluble drug. Flow 33 
cytometric analysis showed that clones expressed chemokine receptors CCR4 (skin homing) 34 
and CXCR3 (migration to peripheral tissue) and one of three distinct TCR Vβs; TCR Vβ 2, 35 
5.1, or 22. These data show the propensity of both R- and S-forms of telaprevir to generate 36 
skin-homing cytotoxic T-cells that may induce the adverse reactions observed in human 37 
patients. 38 
 39 




  44 
Introduction 45 
Hepatitis C (HCV) is a serious, potentially life-threatening viral infection that affects an 46 
estimated 71 million individuals worldwide (WHO, 2017). Although up to a quarter of infected 47 
patients effectively clear the virus (WHO, 2017), the vast majority develop chronic HCV 48 
infection. The associated inflammation ultimately leads to severe liver disease, including 49 
hepatocellular carcinoma, liver fibrosis and cirrhosis, due to which hepatitis C is the most 50 
common indication for liver transplantation in the US (Verna and Brown, 2006). HCV has been 51 
traditionally treated with a dual regimen of PEGylated IFN-α and ribavirin which provide a 52 
sustained antiviral response (<10 IU/ml) in just 39% of patients. In contrast, an updated triple 53 
treatment regimen including telaprevir (TVR, VX-950), increases the frequency of patients that 54 
achieve viral control to 70% (Lang, 2007). Telaprevir is an NS3/4.A protease inhibitor for use 55 
against HCV genotype 1 which prevents both the cleavage of viral proteins into active 56 
polypeptides for viral assembly, and the deactivation of hepatic cellular proteins essential for 57 
mediating the interferon cascade and mounting a viral response (Jesudian et al., 2012;  58 
Morikawa et al., 2011;  Smith et al., 2011). While administered orally as a single S-59 
configurated diastereomer, telaprevir spontaneously forms the corresponding R-diastereomer 60 
(figure 1a, b), which is approximately 30-fold less pharmacologically active (Garg et al., 2012). 61 
 62 
Despite enhanced viral suppression, the triple regimen is associated with an increased risk of 63 
adverse cutaneous reactions, with triple telaprevir-containing therapy causing a severe rash in 64 
4.8% of patients compared to just 0.4% with the standard dual therapy. Of more concern, a 65 
small subset of patients treated with telaprevir develop life-threatening cutaneous drug 66 
hypersensitivity reactions including drug rash with eosinophilia and systemic symptoms 67 
(DRESS) and Stevens Johnson syndrome (SJS) (Pavlos et al., 2012;  Roujeau, 2005;  Roujeau 68 
et al., 2013). These clinical diagnoses, alongside the lack of correlation between the severity 69 
of telaprevir-induced cutaneous reactions and drug plasma concentration, as well as the delayed 70 
onset (median 15 days) and slow resolution (median 44 days) after drug discontinuation, are 71 
indicative of a type IV hypersensitivity reaction (Roujeau et al., 2013). Such delayed drug 72 
hypersensitivity reactions are thought to be mediated by the activation and subsequent 73 
cytotoxic action of drug-specific T-cells, which have been previously isolated from patients 74 
with hypersensitivity to a diverse array of drugs (Kim et al., 2015;  Lichtenfels et al., 2014;  75 
Meng et al., 2017;  Usui et al., 2017). Despite a reported correlation between the level of the 76 
T-cell-derived cytotoxic mediator granulysin and the severity of telaprevir-induced skin 77 
reactions (Suda et al., 2015), telaprevir-specific T-cells have not been identified. Furthermore, 78 
no specific HLA alleles are associated with telaprevir-induced skin reactions of any severity 79 
(Roujeau et al., 2013). 80 
 81 
To circumnavigate the inability of animal models to predict hypersensitivity, in vitro models 82 
that utilise T-cells from healthy human donors have been developed that are successful at 83 
generating and characterising drug-specific T-cells (Bell et al., 2013;  Gibson et al., 2017;  84 
Monshi et al., 2013;  Sullivan et al., 2018). Critically, these assays enable the modulation of 85 
reported susceptibility factors and the identification of the antigen, whether parent compound 86 
or metabolic derivative, responsible for the initial, highly-regulated activation of T-cells. 87 
Telaprevir undergoes extensive hepatic metabolism and forms a range of metabolites, including 88 
M11, which was identified as potentially immunogenic due to a positive read out for skin 89 
sensitizing potential in a guinea pig maximisation test.  (FDA application Number 201917; 90 
Garg et al., 2012) (figure 1c). In order to provide an understanding of telaprevir 91 
immunogenicity, we utilised in vitro peripheral blood mononuclear cell (PBMC) drug bulk 92 
cultures to assess the propensity for telaprevir-derived antigens to activate T-cells isolated from 93 
drug-naïve healthy human donors. 94 
Materials and methods 95 
Isolation of PBMC from drug-naïve healthy human donors: Venous blood samples (120ml) 96 
were taken from seven telaprevir-naïve healthy human donors who had provided informed 97 
written consent as directed by the Liverpool local research ethics committee. A density gradient 98 
separation technique was performed to isolate the PBMC population from whole venous blood 99 
using lymphoprep (Axis-shield, Dundee).  100 
 101 
PBMC bulk culture: PBMCs (1x106/well; 48-well plate; 660ul total) were cultured for 14 102 
days with either the S- or R-diastereomer of telaprevir (5-20uM), or the M11 metabolite 103 
(20µM). Cultures were fed with R9 medium (RPMI 1640, 100 µg/ml penicillin, 100 U/ml 104 
streptomycin, 25 µg/ml transferrin, 10% human AB serum [Innovative Research], 25 mM 105 
HEPES buffer, 2 mM L-glutamine) supplemented with IL-2 on days 6 and 9. On day 14, 106 
cultures for the same antigen but of differing concentrations were harvested and pooled. A 107 
sample of PBMCs were frozen for later use at 10-20 x 106 cells/ml at 1:1 ratio of R9 medium 108 
to 80% human AB serum, 20% DMSO (total volume, 1 ml). Cryovials were stored at -80°C 109 
for 24-48 hrs before transfer to -150°C for longer term storage. Any remaining PBMCs were 110 
used for functional studies. Briefly, 1x105/well antigen-exposed PBMCs were re-exposed in 111 
duplicate wells (96-well plate, 200ul total) to either the S- or R-diastereomer of telaprevir for 112 
48 hours (37°C/5% CO2). Antigen re-exposed cultures were then pulsed with [
3H] thymidine 113 
(0.5 µCi/well) and subject to a further 16 hr incubation before analysis of incorporated 114 
radioactivity as measure of drug-specific proliferation using a Microbeta Trilux 1450 LSC beta 115 
counter (PerkinElmer, Cambridge, U.K.). 116 
 117 
Serial dilution and T-cell cloning: T-cell clones were generated from PBMC bulk cultures 118 
using serial dilution and mitogen-driven expansion (Mauri-Hellweg et al., 1995). Briefly, cells 119 
were plated at 1 cell/well (96well U-bottomed plate) in a restimulation cocktail (5x104 120 
irradiated allogeneic PBMC/well, 10ul/ml PHA, 5ul/ml IL-2) and cultured for 14 days 121 
(37°C/5% CO2). Cultures were fed on day 5 and then every two days subsequently with R9 122 
medium supplemented with IL-2. Additionally, autologous EBV-transformed B-cells (EBV) 123 
were generated from PBMC to function as an immortalised antigen presenting cell line.  124 
 125 
To probe for antigen-specificity, expanded T-cell clones (5 x 104/well; 96 well plate; total 126 
volume, 200 µl) were cultured (37°C/5% CO2) in duplicate per experimental condition with 127 
irradiated autologous EBVs (1 x 104/well) ± the S- or R-diastereomer of telaprevir (10 µM) or 128 
the M11 metabolite (20uM). After 48 h, [3H] thymidine was added before a further 16 h culture 129 
prior to analysis of cellular proliferation by scintillation counting. T cell clones with a 130 
stimulation index (mean cpm drug-treated wells / mean cpm of control wells) of > 1.5 were 131 
repetitively stimulated with allogeneic PBMCs (5x104/well; 96 well plate; total volume, 200 132 
µl) in R9 medium supplemented with PHA (5 µg/ml) and IL-2 for further expansion. 133 
 134 
T-cell clone characterisation assays: Those clones that responded to telaprevir-derived 135 
antigens in a second confirmatory proliferation assay were further expanded and characterised. 136 
To define cross-reactivity between telaprevir diastereomers and the M11 metabolite, T-cell 137 
clones (5 x 104/well; 96 well plate; total volume, 200 µl) were cultured (37°C/5% CO2) in 138 
triplicate with autologous irradiated EBVs (1 x 104/well) and either diastereomer (5-20uM) or 139 
M11 (20uM) for 48 hours prior to proliferative analysis as described above. In order to explore 140 
the requirement for antigen uptake and processing, EBVs were pulsed with telaprevir for 1-16 141 
hrs. After the allotted exposure period, drug-exposed EBVs were washed in PBS and used to 142 
restimulate cells as above in the absence of soluble drug. Alternatively, to determine whether 143 
antigen was presented in the context of MHC, EBVs were first pre-cultured with either MHC 144 
class I or II blocking antibodies or their corresponding isotype controls (5ul; BD Biosciences, 145 
Oxford, UK) for 30mins. MHC blocked EBVs were then washed and included in the 146 
proliferation assay. 147 
 148 
ELISpot was used to characterise the drug-specific release of specific cytokines and cytolytic 149 
molecules from T-cell clones. The release of IFN-γ, IL-13, IL-22, and granzyme B in response 150 
to telaprevir-derived antigens was visualised by the ELISpot procedure provided by the 151 
manufacturer (Mabtech, Nacka Strand, Sweden). Flow cytometry was utilised to characterise 152 
T-cell clone phenotype, including clone CD4+ or CD8+ coreceptor expression, to assess the 153 
expression profile for a defined chemokine receptor panel (CCR1, CCR2, CCR3, CCR4, 154 
CCR5, CCR6, CCR8, CCR9, CCR10, E-cadherin, CLA, CXCR3, CXCR6), and to determine 155 
TCR Vβ protein expression using the IOTest Beta Mark TCR Vβ repertoire kit (Immunotech, 156 
Beckman Coulter, UK). Briefly, aliquots of T-cells were stained with fluorescence-conjugated 157 
antibodies before incubation on ice in the dark for 20 min. Cells were then washed with PBS 158 
and resuspended in 200ul 10% FBS/PBS prior to data acquisition (minimum 5x104 events) 159 
using a FACS CANTO II flow cytometer. Data was analysed using FACS DIVA or Cyflogic 160 
software (CyFlo Ltd., Finland). 161 
 162 
  163 
Results 164 
Weak telaprevir-specific proliferative response from healthy donor-derived T-cell 165 
cultures: PBMC bulk cultures established with either the S- or R-diastereomer of telaprevir 166 
were restimulated every 2-3 weeks to promote further expansion of antigen-specific T-cells. 167 
Cultures with high cell recovery were tested for antigen specificity before being subject to 168 
serial dilution for T-cell cloning. While responses to the model drug immunogen nitroso 169 
sulfamethoxazole (SMX-NO) were clearly detectable from PBMC bulk cultures in all donors 170 
(figure 2), the majority of cultures exposed to telaprevir diastereomers failed to proliferate 171 
(figure 2i, 2ii; representative donors 1-3). However, T-cells from donor 2 responded weakly in 172 
response to the R-diastereomer. 173 
 174 
Identification of CD4+ and CD8+ telaprevir antigen-specific T-cells: To explore whether 175 
telaprevir-specific T-cells are present below the limit of detection in the PBMC assay, T-cell 176 
cloning was performed on cells derived from all 7 telaprevir-exposed cultures. Initial testing 177 
identified the drug-specific proliferation (SI > 1.5) of T-cell clones from 3/7 donors (figure 3). 178 
After expansion, a further triplicate proliferation culture confirmed the presence of telaprevir-179 
responsive T-cell clones. Five and thirty five T-cell clones derived from PBMC cultures 180 
containing the S- and R-diastereomer, respectively remained drug-responsive during repetitive 181 
mitogen-driven expansions and were used for the mechanistic studies described below. 182 
 183 
Irrespective of the antigen used for initial culture, all clones proliferated in the presence of 184 
either diastereomer to a similar extent at similar concentrations (figure 4). Flow cytometry 185 
determined that all telaprevir diastereomer-responsive T-cell clones from donor 3 were CD8+ 186 
T-cells, while a mixed phenotype was observed from the 13 suitable for analysis from donor 187 
2, with 10 CD4+ (76.9%) and 3 CD8+ (23.1%) T-cell clones identified.  188 
 189 
In stark contrast, cloning performed on PBMC bulk cultures with the M11 metabolite from 3 190 
healthy donors failed to identify M11-responsive T-cell clones.  191 
 192 
Telaprevir-responsive T-cells secrete cytotoxic and pro-inflammatory mediators: 193 
ELISpot was utilized to probe for the telaprevir-induced secretion of cytokines and cytolytic 194 
molecules from the CD8+ T-cell clones. All clones secreted IFN-γ to a similar degree upon 195 
exposure to either telaprevir diastereomer (figure 5 - average spot count across 7 clones shown: 196 
IFN-γ; medium, 81 ± 47.9; 10µM S-diastereomer, 282 ± 77.4; 10µM R-diastereomer, 288 ± 197 
53). Drug-induced secretion of IL-13 and the cytotoxic mediator granzyme B was similarly 198 
observed. In stark comparison, none of the aforementioned mediators were secreted when 199 
telaprevir-responsive T-cell clones were exposed to the M11 metabolite (figure 6a). The lack 200 
of cross-reactivity was further confirmed by a negative proliferative response to the M11 201 
metabolite in these clones (figure 6b). Secretion of IL-22 was not detected in response to 202 
telaprevir diastereomers, despite its reported involvement in inflammatory skin conditions 203 
(figures 5 & 6). 204 
 205 
Telaprevir-induced T-cell responses are MHC-restricted and occur independent of 206 
antigen presenting cell processing: To assess the presentation of telaprevir to T-cells, 207 
telaprevir-specific T-cell clones were first cultured with telaprevir-pulsed autologous irradiated 208 
EBV-transformed B-cells free of soluble drug. While T-cells strongly proliferated in response 209 
to soluble drug, they were not stimulated by drug-pulsed antigen presenting cells at either time 210 
point (1 or 16 hrs; figure 7a). Further investigation using HLA blocking antibodies focussed 211 
on the requirement for HLA in the activation of T-cells. The telaprevir-induced CD8+ T-cell 212 
proliferative response was diminished by blocking HLA class I molecules (figure 7b), but not 213 
the corresponding isotype control. These data infer that telaprevir is directly presented on HLA 214 
class I molecules to passing CD8+ T-cells, without a need for antigen uptake and processing. 215 
 216 
Telaprevir responsive T-cells express distinct TCR Vβ and chemokine receptors: To 217 
induce keratinocyte death, telaprevir-responsive T-cells must express specific homing 218 
receptors to promote migration to the skin. The expression of a diverse array of tissue-homing 219 
chemokine receptors was analysed on the drug-responsive T-cell clones, which expressed the 220 
T-cell activation marker CD69. Of the 13 migratory markers assessed, telaprevir-responsive T-221 
cells most highly expressed CCR4 (skin homing; mean fluorescence intensity [MFI]: 3.40 ± 222 
1.04) and CXCR3 (migration to peripheral tissue; MFI: 3.16 ± 1.52) (figure 8 a). Further T-223 
cell surface expression analysis revealed a restricted pattern of TCR-Vβ expression, in which 224 
there was a high expression of TCR-Vβ 22 (n=6, 46%), with fewer clones expressing TCR-Vβ 225 
2 (n=5, 38%) and TCR-Vβ 5.1 (n=1, 8%). Of note, one clone expressed no identifiable TCR 226 
Vβ covered by the kit, which recognises 24 specificities that account for 70% of the total 227 
repertoire (figure 8b). Thus, it is likely this T-cell clone expressed another alternative TCR-228 
Vβ. 229 
  230 
Discussion 231 
As the acute stage of HCV is largely asymptomatic, the majority of patients develop a chronic 232 
infection that leads to long term, life threatening liver complications. An adaptation of the 233 
standardised dual therapy, by co-administration of telaprevir, led to > 30% increase in 234 
therapeutic response rate. However, telaprevir also enhanced the incidence of mild skin 235 
reactions, and led to a number of patients developing life threatening hypersensitivity reactions 236 
including DRESS and SJS. The appearance of new drugs with improved safety profile resulted 237 
in telaprevir being withdrawn from the market.  238 
 239 
Drug-specific T-cells have been isolated from the blood and blister fluid of patients with other 240 
forms of severe hypersensitivity reaction, and these T-cells are thought to mediate tissue 241 
destruction. However, as yet telaprevir-responsive T-cells have not been identified or 242 
characterized in terms of phenotype and function. While samples from hypersensitive patients 243 
are informative for clinical diagnosis, they represent a memory T-cell response, and give no 244 
indication regarding the ability of the antigen to activate the more highly regulated naïve 245 
population. Thus, using PBMC drug bulk cultures we probed the immunogenicity of the 246 
telaprevir S- and R-diastereomers. 247 
 248 
Telaprevir-responsive T-cell clones were generated from 3 out of 7 healthy volunteers; 249 
however, the frequency of identifiable drug-responsive T-cell clones was low. Although 250 
administered as the S-diastereomer, telaprevir spontaneously converts to the R-diastereomer in 251 
vivo. A study on Japanese HCV patients showed that the mean Cmax for telaprevir was 5.4 µM 252 
at steady state (Yamada et al., 2012), where maximal plasma concentrations of the R-253 
diastereomer were almost equivalent to those of the S-diastereomer (Nakada et al., 2014). In 254 
our study, T-cell clones were derived from PBMC cultured with both the S- and R-255 
diastereomer. In contrast to the diastereomer-specific actions of telaprevir at its 256 
pharmacological target, the hepatitis C viral enzyme NS3/4A serine protease, a high degree of 257 
T-cell cross reactivity was observed with both diastereomers. In fact, the same concentrations 258 
of S- and R-diastereomer were capable of inducing proliferate responses to a similar degree. 259 
While these data imply the parent compound is responsible for T-cell activation, the formation 260 
of a metabolite after internalisation by antigen presenting cells and subsequent presentation on 261 
HLA to passing T-cells is a possibility. One potentially immunogenic metabolite is M11, as it 262 
has previously been reported to induce a positive guinea pig maximisation test. Telaprevir-263 
responsive T-cell clones failed to respond to M11, and moreover, cloning directly using the 264 
M11 metabolite was unsuccessful in 3 donors, including the donors who provided clones 265 
responsive towards the parent compound. While this inter-species differential response may 266 
relate to the small number of animals or humans tested between the two studies, it nonetheless 267 
stresses the importance of assessing antigenicity and immunogenicity using human models.  268 
 269 
Telaprevir is a reversible covalent binding inhibitor of its pharmacological target. The drug 270 
interacts with a high degree of specificity with serine in position 139, which resides in the 271 
catalytic area of the protease enzyme. Dissociation of the covalently bound drug has a half-life 272 
of 58 minutes (Fowell and Nash, 2010). To investigate whether the telaprevir-responsive T-273 
cells were activated through the formation of protein adducts by a hapten mechanism or 274 
through direct HLA binding, antigen presenting cell pulsing experiments were conducted. 275 
Haptenic drugs bind irreversibly to antigen presenting cells in the pulsing assay and stimulate 276 
T-cells after repeated washing to remove the non-covalently-bound drug. In contrast, drugs that 277 
bind directly to HLA through a reversible bond yield a negative result (Alzahrani et al., 2017;  278 
Castrejon et al., 2010;  Schnyder et al., 2000). While the telaprevir-specific T-cell response 279 
was MHC restricted, the T-cells were only activated in the presence of soluble drug, 280 
highlighting that formation of a covalent adduct, antigen-uptake and processing by antigen 281 
presenting cells is not a requirement for T-cell activation. These data indicate that telaprevir 282 
may be able to activate T-cells expressing distinct TCR Vβs via a direct HLA binding 283 
interaction. Interestingly, telaprevir is relatively large, with a molecular weight of 680Da. This 284 
equates to the over 50% of the mass of a typical HLA class I binding peptide (assuming an 285 
average amino acid mass of 130Da and 9-10 amino acids in the peptide sequence). Thus, it will 286 
be intriguing to discover the structure of the telaprevir HLA peptide binding interaction. It 287 
seems unlikely that telaprevir will fit into a binding pocket under an HLA binding peptide. The 288 
only other possibilities are that telaprevir (1) interacts with the HLA binding peptide and 289 
projects from the HLA molecule, (2) replaces the requirement for an HLA binding peptide or 290 
(3) binds elsewhere on the HLA molecule altering the structure of the HLA binding cleft. 291 
 292 
CD8+ T-cells are designed to inflict damage and thus are the most likely mediators of 293 
keratinocyte death in patients with telaprevir hypersensitivity. Thus, CD8+ cells were analysed 294 
for their cytokine secretion profile and the secretion of cytolytic molecules using ELISpot. 295 
Previously Suda et al reported a correlation between the level of the cytotoxic mediator 296 
granulysin and the severity of telaprevir-induced skin reactions. Moreover, they describe an 297 
early rise in serum granulysin levels with the onset of severe symptoms which fades within 6 298 
days and therefore concluded that granulysin can be utilized as an early predictive marker for 299 
telaprevir-induced skin reactions (Suda et al., 2015). In agreement with the induction of a 300 
cytotoxic response, telaprevir-responsive CD8+ T-cell clones not only secreted IFN-γ and IL-301 
13, but also the cytotoxic mediator granzyme B in response to culture with either diastereomer. 302 
Upon release from cytotoxic T-cell granules, granzyme B enters target cells to cleave caspases 303 
and initiate apoptosis. The secretion of IL-22 was additionally monitored due to its proposed 304 
role in inflammatory skin conditions, including psoriasis. Furthermore, IL-22-secreting cells 305 
have been identified in patients with allergic contact dermatitis and β-lactam hypersensitivity 306 
reactions (Akdis et al., 2012;  Cavani et al., 2012;  Eyerich et al., 2010;  Sullivan et al., 2018). 307 
IL-22 was not secreted by telaprevir-responsive T-cells in this study. 308 
 309 
Chemokine receptor pattern analysis on telaprevir-responsive T-cell clones detected a 310 
population with a skin-homing phenotype.  While the skin homing receptor CCR10 was 311 
present, CCR4 and CXCR3 were also highly expressed. CXCR3  is predominantly expressed 312 
by Th1 T-cells while CCR4 is expressed by Th2 T-cells (Kim et al., 2001). These findings, 313 
along with the antigen-specific secretion of IFN-γ (Th1) and IL-13 (Th2), suggest the presence 314 
of a mixed Th1/2 T-cell population. CCR9, characterised as a gut homing receptor for T-cells 315 
with a role in intestinal inflammation (Agace, 2008;  Bekker et al., 2015), was also relatively 316 
highly expressed in comparison to other chemokine receptors. Interestingly, adverse intestinal 317 
effects with telaprevir hypersensitivity is very common ranging from diarrhoea to 318 
haemorrhoids in 25% and 12% of patients, respectively. As yet, the underlying mechanism of 319 
intestinal disruption is not defined, but this data indicates the migration of T-cells may play a 320 
role. 321 
 322 
This study identifies and characterises the telaprevir-induced activation of T-cells from 3 out 323 
of 7 healthy drug-naïve donors that develop into skin-homing, cytotoxic T-cells, which are 324 
activated by an HLA-restricted but processing-independent mechanism. Drug-specific T-cells 325 
responded to either telaprevir diastereomer and expressed varied TCRs. Drug-responsive T-326 
cells were induced using cultures from drug-naïve healthy donors and so define the utility of 327 
in vitro human platforms to explore the requirements for T-cell activation. As studies have 328 
previously failed to associate telaprevir hypersensitivity with HLA risk alleles (Roujeau, et al., 329 
2013), the development of in vitro human assays to allow (a) modulation of other immune 330 
parameters and (b) inclusion of autologous keratinocytes will be key to understand the inter-331 
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  465 
Figure legends 466 
Figure 1. Chemical structures of the (A) S- (therapeutic form) and (B) R-diastereomers 467 
of telaprevir and (C) the M11 metabolite. 468 
 469 
Figure 2 Healthy donor T-cell responses from PBMC bulk cultures with the telaprevir (i) 470 
S- diastereomer (ii) R-diastereomer (5-20uM), or (iii) SMX-NO (25-50uM; model drug-471 
derived immunogen). PBMCs (1x106/well; 48-well plate; 660ul total) were directly cultured 472 
with antigen for 14 days prior assessment of drug specificity. [3H]thymidine (0.5 µCi/well) was 473 
added for the final 16 hr of the incubation and then incorporated radioactivity was measured. 474 
Data shown as proliferative stimulation index (SI; average of drug-exposed wells / average of 475 
control wells). Error bars indicate standard deviation for the average of replicate cultures. 476 
 477 
Figure 3. Generation of telaprevir-responsive T-cell clones. Telaprevir diastereomer-478 
exposed T-cells from PBMC bulk cultures were subject to serial dilution and mitogen-driven 479 
expansion. Individual T-cell clones (5 x 104/well; 96 well plate; total volume, 200 µl) were 480 
cultured (37°C/5% CO2) in duplicate per experimental condition with irradiated autologous 481 
EBVs (1 x 104/well) ± the drug antigen. After 48 h, [3H] thymidine was added before a further 482 
16 h culture prior to analysis of cellular proliferation by scintillation counting. T cell clones 483 
with a stimulation index (mean cpm drug-treated wells / mean cpm of control wells) of > 1.5 484 
were selected as drug-responsive and subject to further expansion and investigation. 485 
 486 
Figure 4. Cross-reactivity between telaprevir-diastereomers. Drug-responsive T-cell 487 
clones (5 x 104/well; 96 well plate; total volume, 200 µl) generated from initial cultures with 488 
either the R- or S-diastereomers were cultured (37°C/5% CO2) in triplicate with autologous 489 
irradiated EBV-transformed B-cells (1 x 104/well) and either diastereomer (5-20uM) for 48 490 
hours prior to pulsing with [3H]thymidine (0.5 µCi/well). After a further 16 hr incubation,  491 
incorporated radioactivity was counted as a measure of proliferation. Data presented as 492 
radioactive counts per minute (cpm); error bars indicate the standard deviation for the average 493 
of triplicate cultures. 494 
 495 
Figure 5. Cytokine and cytolytic molecule secretion from telaprevir-responsive T-cell 496 
clones. ELISpot plates were coated with IFN-γ, IL-13, IL-22, or granzyme B capture antibody 497 
and incubated at 4°C overnight. Wells were then washed and blocked with R9 medium. T-cell 498 
clones (5x104/well; total volume, 200 µl, 96-well U-bottomed ELISpot plate) were cultured 499 
with the S- (5-10uM) or R-diastereomer of telaprevir and autologous irradiated EBV-500 
transformed B-cells (1x104/well). After a 48 hr incubation, the plates were washed and 501 
developed in concordance with the manufacturer’s instructions. Spot forming units (SFU) 502 
counts were analysed from dry wells using an ELISpot reader. 503 
 504 
Figure 6. Ability of the M11 metabolite to induce (A) cytokine or cytolytic molecule 505 
secretion or (B) a proliferative response in telaprevir-responsive T-cell clones. ELISpot 506 
plates were coated with IFN-γ, IL-13, IL-22, or granzyme B capture antibody and incubated at 507 
4°C overnight. Wells were then washed and blocked with R9 medium.  For both proliferation 508 
and ELISpot assays, T-cell clones (5x104/well; total volume, 200 µl, 96-well plate) were then 509 
cultured with telaprevir (10uM) or the M11 metabolite (20uM) and autologous irradiated EBV-510 
transformed B-cells (1x104/well). After a 48 hr incubation, the ELISpot plates were washed 511 
and developed in concordance with the manufacturer’s instructions. SFU counts were analysed 512 
from dry wells using an ELISpot reader. Alternatively, plates for proliferation analysis were 513 
pulsed with [3H] thymidine (0.5 µCi/well) and subject to a further 16 hr incubation before 514 
measurement of incorporated radioactivity. Data presented as radioactive counts per minute 515 
(cpm), error bars indicate the standard deviation for the average of triplicate cultures. 516 
 517 
Figure 7. Requirement for (A) antigen uptake and (B) HLA restriction for T-cell 518 
activation. Autologous EBV were either (A) pulsed with soluble drug for 1-16 hrs prior to 519 
washing to remove free drug, or (B) cultured with HLA blocking antibodies or their respective 520 
isotype controls for 30 mins. T-cell clones (5x104/well; total volume, 200 µl, 96-well plate) 521 
were then cultured with telaprevir (10-20uM) and pre-conditioned autologous irradiated EBV-522 
transformed B-cells (1x104/well). After a 48 hr incubation, cultures were pulsed with [3H] 523 
thymidine (0.5 µCi/well) and subject to a further 16 hr incubation before measurement of 524 
incorporated radioactivity. Data presented as radioactive counts per minute (cpm), error bars 525 
indicate the standard deviation for the average of triplicate cultures. 526 
 527 
Figure 8. TCR Vβ and chemokine profile of telaprevir-responsive T-cell clones. T-cell 528 
clones (5x104) were washed and stained with (A) individual Fluorochrome-conjugated 529 
antibodies specific for chemokine receptors or (B) combined Fluorochrome-conjugated 530 
antibodies specific for TCR Vβ specificities. Samples were left in the dark for 20 mins at 4°C 531 
to aid antibody binding. After which samples were washed to remove unbound antibody and 532 
fixed in 4% PFA prior to analysis using a BD FACS CANTO II flow cytometer. Data analysis 533 
was performed using cyflogic software. 534 
  535 
Figure 1 536 
 537 
  538 
(A) Telaprevir (S-diastereomer)
(B) R-diastereomer
(C) M11 metabolite (VRT-841125)
Figure 2 539 
  540 
Donor 1 Donor 2 Donor 3
Figure 3 541 
 542 
 543 














































































Figure 4 545 






































medium 5uM R-diastereomer 10uM R-diastereomer 20uM R-diastereomer 20uM telaprevir
T-cell clones derived from R-diastereomer cultures






clone 13 clone 77
medium 5uM telaprevir





















clone 134 clone 27
medium 5µM telaprevir

























Figure 5 547 




















Figure 6 549 
  550 
Clone 117












M11 metabolite 20 µM
GB IL-13





clone 134 clone 27















Figure 7 551 
 552 









































10uM Telaprevir + MHC I block
10UM telaprevir + MHC I isotype
10uM Telaprevir + MHC II block



















Figure 8 554 
 555 
0
M
e
a
n
 fl
u
o
re
sc
en
ce
 I
n
te
n
si
ty
 (M
FI
)
1.0
2.0
3.0
4.0
5.0
(A)
(B)
